Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Botulinum toxin for spastic gastrointestinal disorders.

W A Hoogerwerf1, P J Pasricha

  • 1University of Texas Medical Branch, Galveston, USA.

Bailliere'S Best Practice & Research. Clinical Gastroenterology
|October 13, 2000
PubMed
Summary

Botulinum toxin (BTX) offers a safe and effective treatment for various gastrointestinal spastic disorders. Its targeted application shows promise for managing conditions like achalasia and anal fissures, with ongoing research into broader uses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Computational modeling of drug dissolution in the human stomach: Effects of posture and gastroparesis on drug bioavailability.

Physics of fluids (Woodbury, N.Y. : 1994)·2022
Same author

The 2018 ISDE achalasia guidelines.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2018
Same author

Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis.

Neurogastroenterology and motility·2017
Same author

Esophageal distensibility measurement: impact on clinical management and procedure length.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2017
Same author

Diabetic and idiopathic gastroparesis is associated with loss of CD206-positive macrophages in the gastric antrum.

Neurogastroenterology and motility·2017
Same author

Anorectal manometry: Should it be performed in a seated position?

Neurogastroenterology and motility·2016

Area of Science:

  • Gastroenterology
  • Neurology
  • Pharmacology

Background:

  • Botulinum toxin (BTX) is a potent acetylcholine inhibitor with established therapeutic uses in neuromuscular syndromes.
  • Gastrointestinal (GI) spastic disorders represent a growing area for BTX application.
  • Understanding BTX's mechanism and efficacy is crucial for treating motility disorders.

Purpose of the Study:

  • To review the expanding use of botulinum toxin (BTX) in treating spastic gastrointestinal disorders.
  • To evaluate the efficacy and safety of BTX injections for specific GI conditions.
  • To explore potential future applications of BTX in gastroenterology.

Main Methods:

  • Review of existing literature on botulinum toxin (BTX) applications in gastrointestinal motility disorders.

Related Experiment Videos

  • Analysis of short-term efficacy data for conditions such as achalasia and anal fissures.
  • Examination of ongoing research into BTX for other GI sphincteric and non-sphincteric syndromes.

    • Main Results:

    • Short-term efficacy of intrasphincteric BTX injections is well-established for achalasia.
    • BTX demonstrates significant benefit in chronic anal fissures, with a relatively short duration of action being advantageous.
    • Efficacy is under active investigation for non-cardiac chest pain, post-operative pylorospasm, and sphincter of Oddi dysfunction.
    • BTX injections into skeletal muscle sphincters (e.g., upper esophageal, anal) show positive effects.
    • Local BTX injection can serve as a therapeutic trial for guiding further treatment decisions.

    Conclusions:

    • Botulinum toxin (BTX) is a relatively simple and safe therapy for GI motility disorders based on current short-term data.
    • BTX represents a novel approach with expanding successful applications in gastroenterology.
    • Further studies are needed to assess the long-term outcomes of BTX treatment in GI conditions.